Study of Cost-effectiveness and Safety of 0.2% Olopatadine in Comparison with Combination of 0.1% Olopatadine and 0.4% Ketorolac Eye Drops in Vernal Keratoconjunctivitis among Rural Population
Abstract
The study aimed to compare the cost-effectiveness and safety of 0.2% Olopatadine with a combination of 0.1% Olopatadine and 0.4% Ketorolac eye drops in Vernal keratoconjunctivitis (VKC) among the rural population. This was a randomized, open-label, prospective study conducted on 129 patients who were diagnosed with VKC. All the patients were randomly allotted to 2 treatment groups. Group 1 received 0.2% Olopatadine eye drops/single drops/three times a day. Group 2 treated with a combination of 0.1% Olopatadine and 0.4% Ketorolac eye drops/single drops/two times a day for four weeks. The patients were advised to follow up during the study period in the second and fourth weeks. During the follow-ups, post-intervention cure rate, adverse drug reactions (ADR) monitoring, and cost-effectiveness of both the drugs were evaluated. A statistically significant (p<0.05) reduction of clinical symptoms was observed in both groups after four weeks of treatment. In 0.2% Olopatadine intervention, 9 cases of ADR were reported out of the 62 patients. Furthermore, treatment with a combination of 0.1% Olopatadine and 0.4% Ketorolac has shown 12 cases from 58 having ADR. Our study revealed that the 0.2% Olopatadine eye drops were a comparatively affordable choice since the cost was less. Therefore, 0.2% Olopatadine is considered a better drug choice in the given scenario of the rural population regarding their safety and cost-effectiveness.
Keywords
Full Text:
PDFReferences
De Castro G, Midulla F, Leonardi L, et al. Vernal Keratoconjunctivitis: an update focused on the clinical grading system. Italian Journal of Pediatrics. 2019;45(1):1-6.
Singhal D, Sahay P, Maharana PK, Raj N, Sharma N, Titiyal JS. Vernal keratoconjunctivitis. Survey of Ophthalmology. 2019;64(3):289-311.
Deepa R, Reddy CS. Comparative Study between Olopatadine 0.1% and Cyclosporine 0.05% Eye Drops in Children with Vernal Keratoconjunctivitis. Annals of the Romanian Society for Cell Biology. 2021;25(4):8277-8288.
Alemayehu AM, Yibekal BT, Fekadu SA. Prevalence of vernal keratoconjunctivitis and its associated factors among children in Gambella town, southwest Ethiopia, 2018. PLoS ONE. 14(4): e0215528.
Chigbu DI, Labib BA. Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives. Pharmaceuticals. 2021;14(7):1-22.
Addis H, Jeng BH. Vernal keratoconjunctivitis. Clinical Ophthalmology. 2018;12(1):119-123.
Leonardi A. Management of vernal keratoconjunctivitis. Ophthalmology and Therapy. 2013;2(2):73-88.
Chigbu DI, Labib BA. Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives. Pharmaceuticals. 2021;14(7):1-22.
Gokhale NS. Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a treatment algorithm. Indian journal Ophthalmology. 2016;64(2):145-148.
Sruthi V, Reddy RN, Sowmini K, Grace NS. To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital. Indian Journal of Pharmacology. 2020;52(6):476-481.
Torkildsen G, Narvekar A, Bergmann M. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model. Clinical Ophthalmology. 2015;9(1):1703-1713.
Meena RK, Gupta ML, Sharma HP. A comparative study of Olopatadine and Ketorolac eye drop with Ketorolac eye drop alone in seasonal allergic conjunctivitis. International Journal of Medical Research and Review. 2017;5(09):829-838.
Roumeau I, Coutu A, Navel V, Pereira B, Baker JS, Chiambaretta F, et al. Efficacy of medical treatments for vernal keratoconjunctivitis: a systematic review and meta-analysis. Journal of Allergy and Clinical Immunology. 2021;148(3):822-834.
Esposito S, Fior G, Mori A, Osnaghi S, Ghiglioni D. An update on the therapeutic approach to vernal keratoconjunctivitis. Pediatric Drugs. 2016;18(5):347-355.
Ridolo E, Montagni M, Caminati M, Senna G, Incorvaia C, Canonica GW. Emerging drugs for allergic conjunctivitis. Expert Opinion on Emerging Drugs. 2014;19(2):291-302.
Meier E, Narvekar A, Iyer GR, DuBiner HB, Vutikullird A, Wirta D, et al. Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies. Clinical Ophthalmology. 2017;11(1):669-681.
Kumar R, Singh RK. Comparative evaluation of Ketorolac alone and Ketorolac with Olopatadine eye drop for allergic conjunctivitis. International Journal of Health and Clinical Research. 2020;3(10):161-168.
Zyaambo C, Siziya S, Fylkesnes K. Health status and socio-economic factors associated with health facility utilization in rural and urban areas in Zambia. BMC Health Services Research. 2012;12(1):1-8.
Jones SM, Du Y, Panattoni L, Henrikson NB. Assessing worry about affording healthcare in a general population sample. Frontiers in Psychology. 2019;10(1):1-8.
Larkin J, Foley L, Smith SM, Harrington P, Clyne B. The experience of financial burden for people with multimorbidity: A systematic review of qualitative research. Health Expectations. 2021;24(2):282-295.
Erdogan H, Cam O. The effect of topical antihistamines used single dose daily in allergic conjunctivitis. The Open Ophthalmology Journal. 2018;12(1):330-337
DOI: https://doi.org/10.15416/pcpr.v7i2.37692
Refbacks
- There are currently no refbacks.
